Chimeric HEV VLPs for Oral Mucosal Antigen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine delivery methods face challenges in effectively targeting mucosal tissues for immune response induction, particularly for hepatitis E virus (HEV), and existing technologies struggle to efficiently deliver both amino acid and DNA-based antigens to these sites.
Innovation Solution
A modified hepatitis E virus (HEV) capsid protein is used to form chimeric virus-like particles (VLPs) that encapsulate heterologous nucleic acids and peptides, allowing for oral administration and mucosal immune response induction, with the capability to self-assemble and deliver antigens to intestinal mucosa.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccine delivery methods are used, then systemic immune response can be induced, but effective targeting of mucosal tissues is achieved poorly
Solution Approach 1:
The vaccine delivery system is segmented into two functional components: HEV VLPs that target intestinal mucosa and carry peptide antigens, while separate DNA plasmids provide cellular immunity. This segmentation allows each component to optimize for its specific function, with VLPs handling mucosal targeting and peptide presentation, while DNA handles cellular response.
Solution Approach 2:
HEV VLPs serve as intermediary carriers that bridge the gap between oral administration and mucosal immune response. The VLPs act as natural vectors that the intestinal mucosa accepts, delivering peptide antigens directly to mucosal tissues without requiring adjuvants or complex delivery systems.
2Adaptability or versatility
If both amino acid and DNA-based antigens are delivered, then comprehensive immune response is achieved, but delivery complexity increases
Solution Approach 1:
The invention merges peptide antigen delivery and DNA plasmid delivery into a single oral administration formulation. The HEV VLPs carry peptide antigens while the DNA plasmids are co-administered, creating a unified delivery system that provides both humoral and cellular immunity through one simple oral dose.
Solution Approach 2:
The oral delivery system is designed to be universal, accommodating both peptide antigens (via VLP carriers) and DNA plasmids through the same administration route. This multi-functional approach allows the system to induce both humoral and cellular immune responses without requiring separate delivery mechanisms.
3Reliability
If adjuvants are used to enhance immune response, then immune efficacy improves, but formulation complexity and potential side effects increase
Solution Approach 1:
The HEV VLPs provide self-service by naturally inducing mucosal immune responses through their own structural features and peptide antigen presentation. The VLPs inherently possess the ability to activate B cells and T cells at the mucosal surface without requiring external adjuvants, simplifying the formulation while maintaining efficacy.
Solution Approach 2:
The invention changes the key parameter of immune activation from adjuvant-dependent to antigen-presenting cell-dependent. By using HEV VLPs that naturally interact with mucosal immune cells, the system achieves effective immune responses through modified biological parameters rather than chemical adjuvants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HEV VLPs induce significant humoral and cellular immune responses, including specific IgM, IgG, and IgA production, as well as CTL responses, effectively conferring immunity to mucosal tissues without the need for adjuvants, demonstrating a promising approach for mucosal vaccine delivery.
Implementation Method 1
The modified HEV capsid protein is able to self-assemble into chimeric virus-like particles (VLPs)
Implementation Method 2
the HEV VLP is able to stimulate humoral immune response and significant level of IgM and IgG antibodies to the inserted epitope
Implementation Method 3
mice used in the study exhibited CTL response specific to gp120 in the spleen, Payer's patches and mesenteric lymph modes
Implementation Method 4
the HEV VLP can disassemble and reassemble in vitro with the ability of encapsidating DNA plasmids. With this method, the HEV VLP is demonstrated to deliver DNA plasmid encoding human immunodeficiency virus (HIV) gp120 into the intestinal mucosa
Data Source
AI summary
This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.